Pregled bibliografske jedinice broj: 833513
Recent advances and ongoing challenges in development of protective vaccine against hepatits C virus
Recent advances and ongoing challenges in development of protective vaccine against hepatits C virus // 1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014)
Opatija, Hrvatska, 2014. (pozvano predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 833513 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Recent advances and ongoing challenges in development of protective vaccine against hepatits C virus
Autori
Smolić, Martina
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014)
Mjesto i datum
Opatija, Hrvatska, 11.09.2014. - 13.09.2014
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Hepatitis C virus; HCV infection; RNA virus
Sažetak
Hepatitis C virus (HCV) infection has emerged as a major viral pandemic. The most cost effective means of controlling infectious disease is through vaccination, however, despite the progress in understanding immunity against HCV infection and its pathogenesis, a prophylactic anti-HCV vaccine is still not available. It is estimated that two million new HCV infections will occur every year because of lacking of anti-HCV vaccine. HCV is a small, enveloped positive sense RNA virus within the Flaviviridae family, classified into 7 major genotypes, and over 50 subtypes with significant heterogeneity. Individuals infected with HCV harbor a multitude of closely related viruses referred to as quasispecies. The degree of sequence variation observed for HCV exceeds that for HIV and influenza, posing a major challenge to vaccine development. The effectiveness of all currently licensed viral vaccines relies on the production of neutralizing antibody (NAb). Strong evidence now exists that NAbs play a major role in clearance of HCV infections as well, however, the virus has developed a number of immune evasion strategies to limit the effectiveness of the NAb response. Vaccine development against HCV is hampered by considerable genetic heterogeneity of HCV isolates, evolution and existence of quasispecies in infected individual and by limited knowledge of defined immunological correlates of protection. Future studies aimed at resolving identified obstacles will provide essentials for the rational design of anti- HCV vaccine.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
